Lumida
/BTI
⌘K
British American Tobacco plc

British American Tobacco plc

BTI
$62.84USD-0.51%-0.32 today

MARKET CAP

74.6B

P/E (TTM)

8.8x

FWD P/E

8.8x

DAY RANGE

$62 – $64

52W RANGE

$48
$66

AI Summary

Stalk
StalkMedium

Momentum breakout confirms the Stage 2 advancing regime with a bullish medium- and long-term structure. Price is currently extended above rising EMAs after the breakout, making immediate execution unfavorable. Execution should be deferred to pullbacks into the rising 9EMA/20EMA zone or the prior resistance-turned-support region near the breakout level. Under the Stable strategy, focus remains on high-quality pullback entries rather than chasing strength.

  • Modern oral segment revenue surged 48% in Q4, led by VeloPlus.
  • £1.3 bn share buyback for 2026 announced alongside 5.75% dividend yield.
  • Regulatory clampdown on illicit vapor products pressures cigarette sales.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

British American Tobacco plc (BTI) is a leading multinational company in the tobacco industry. It has a dominant position within the conventional combustibles market but is actively transitioning toward a more sustainable future by focusing on smokeless products. The strategic pivot towards modern oral and vapor categories reflects a proactive response to changing consumer preferences and regulatory pressures. The company's robust product portfolio and commitment to innovation position it as a key player in the ongoing transformation of the nicotine landscape.

Bull says

  • Modern oral segment revenue surged 48% in Q4, led by VeloPlus.
  • £1.3 bn share buyback for 2026 announced alongside 5.75% dividend yield.
  • Operating cash conversion >90% with £50 bn free cash flow guided by 2030.
  • Analyst consensus ‘Strong Buy’ (avg. $66 PT) after Morgan Stanley upgrade.
  • Strong growth and momentum factors suggest further price appreciation.

Bear says

  • Regulatory clampdown on illicit vapor products pressures cigarette sales.
  • Organic combustibles volume declined 6.9%, undermining core revenues.
  • Negative earnings yield and falling analyst revisions signal returns risk.
  • Elevated leverage heightens debt servicing risk amid macro uncertainty.
  • Declining institutional ownership suggests waning investor confidence.

Investment themes with BTI

Tobacco +0.22%

Producers and distributors of tobacco products

BTI · TPB · JAPAY
United Kingdom +0.36%

Stable developed market with finance and pharmaceuticals

EWU · RIO · GSK

Earnings Call · Q4 2025 · Mgmt. Guidance

Updated 05-06-2026neutral

Transcript signals

Bull points

  • we delivered results at the top end of guidance on a constant currency basis, driven by return to growth in the U.S., a robust performance in AME, and the strength of Modern Oral globally.
  • We delivered group results at the top end of guidance supported by accelerated momentum through the second half. Group revenue increased by 2.1%. Adjusted profit rose 3.4%. Adjusted profit from operations grew 2.3%. And adjusted diluted EPS was up 3.4%.
  • We delivered a 4.6% increase in revenue with our strengthened portfolio, sharper execution, and enhanced revenue growth management driving price mix.

Bear points

  • 50% of the market is illegal today in vapor, and this is a demonstration of how difficult the governments find to either regulate, but more important, to enforce regulation in some markets.
  • growth in key markets including Pakistan, Nigeria, and Indonesia was more than offset by fiscal and regulatory headwinds in Bangladesh and Australia. Total revenue declined 7.2%, with combustibles down 8.3%. New category revenue was down 7.6%.
  • Adjusted profit was down 17.9%, mainly due to challenges in Bangladesh and Australia.
Read full transcript analysis ›